Antibody-independent B cell effector functions in relapsing remitting Multiple Sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity

References

• Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, Waubant E, Gazda S, Fox RJ, Panzara M, Sarkar N, Agarwal S, Smith CH. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008; 63 3: 395–400.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CHB-cell. depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358 7: 676–688.
   PubMed Web of Science ®Google Scholar
• Marriott JJ, O'Connor PW. Emerging therapies in relapsing-remitting multiple sclerosis. Rev Recent Clin Trials. 2010; 5 3: 179–188.
   Google Scholar
• Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011; 378 9805: 1779–1787.
   PubMed Web of Science ®Google Scholar
• Weber MS, Prod'homme T, Patarroyo JC, Molnarfi N, Karnezis T, Lehmann-Horn K, Danilenko DM, Eastham-Anderson J, Slavin AJ, Linington C, Bernard CC, Martin F, Zamvil SSB-cell. activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol. 2010; 68 3: 369–383.
   PubMed Web of Science ®Google Scholar
• Lyons JA, Ramsbottom MJ, Cross AH. Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein. Eur J Immunol. 2002; 32 7: 1905–1913.
   PubMed Web of Science ®Google Scholar
• Lyons JA, San M, Happ MP, Cross AH. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol. 1999; 29 11: 3432–3439.
   Google Scholar
• Monson NL, Cravens P, Hussain R, Harp CT, Cummings M, de Pilar Martin M, Ben LH, Do J, Lyons JA, Lovette-Racke A, Cross AH, Racke MK, Stuve O, Shlomchik M, Eagar TN. Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. PLoS One. 2011; 6 2: e17103.
   PubMed Web of Science ®Google Scholar
• Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med. 1998; 188 9: 1679–1689.
   PubMed Web of Science ®Google Scholar
• Agematsu K, Hokibara S, Nagumo H, Komiyama A. CD27: a memory B-cell marker. Immunol Today. 2000; 21 5: 204–206.
   PubMedGoogle Scholar
• Wagle NM, Cheng P, Kim J, Sproul TW, Kausch KD, Pierce SKB-lymphocyte. signaling receptors and the control of class-II antigen processing. Curr Top Microbiol Immunol. 2000; 245 2: 101–126.
   Google Scholar
• Pascual V, Liu YJ, Magalski A, de Bouteiller O, Banchereau J, Capra JD. Analysis of somatic mutation in five B cell subsets of human tonsil. J Exp Med. 1994; 180 1: 329–339.
   PubMed Web of Science ®Google Scholar
• Tangye SG, Avery DT, Deenick EK, Hodgkin PD. Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses. J Immunol. 2003; 170 2: 686–694.
   PubMed Web of Science ®Google Scholar
• Good KL, Avery DT, Tangye SG. Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells. J Immunol. 2009; 182 2: 890–901.
   Google Scholar
• Gagro A, Servis D, Cepika AM, Toellner KM, Grafton G, Taylor DR, Branica S, Gordon J, Type I. cytokine profiles of human naive and memory B lymphocytes: a potential for memory cells to impact polarization. Immunology. 2006; 118 1: 66–77.
   Google Scholar
• Niino M, Hirotani M, Miyazaki Y, Sasaki H. Memory and naive B-cell subsets in patients with multiple sclerosis. Neurosci Lett. 2009; 464 1: 74–78.
   Google Scholar
• Haas J, Bekeredjian-Ding I, Milkova M, Balint B, Schwarz A, Korporal M, Jarius S, Fritz B, Lorenz HM, Wildemann B. B cells undergo unique compartmentalized redistribution in multiple sclerosis. J Autoimmun. 2011; 37 4: 289–299.
   Google Scholar
• Sellebjerg F, Bornsen L, Khademi M, Krakauer M, Olsson T, Frederiksen JL, Sorensen PS. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009; 73 23: 2003–2010.
   PubMed Web of Science ®Google Scholar
• McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol. 2005; 23:487–513.
   PubMed Web of Science ®Google Scholar
• Markovic-Plese S, Fukaura H, Zhang J, al-Sabbagh A, Southwood S, Sette A, Kuchroo VK, Hafler DA. T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans. J Immunol. 1995; 155 2: 982–992.
   Google Scholar
• Hafler DA, Benjamin DS, Burks J, Weiner HL. Myelin basic protein and proteolipid protein reactivity of brain- and cerebrospinal fluid-derived T cell clones in multiple sclerosis and postinfectious encephalomyelitis. J Immunol. 1987; 139 1: 68–72.
   Google Scholar
• Crawford MP, Yan SX, Ortega SB, Mehta RS, Hewitt RE, Price DA, Stastny P, Douek DC, Koup RA, Racke MK, Karandikar NJ. High prevalence of autoreactive, neuroantigen-specific CD8+T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood. 2004; 103 11: 4222–4231.
   PubMed Web of Science ®Google Scholar
• Karandikar NJ, Crawford MP, Yan X, Ratts RB, Brenchley JM, Ambrozak DR, Lovett-Racke AE, Frohman EM, Stastny P, Douek DC, Koup RA, Racke MK. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest. 2002; 109 5: 641–649.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Antel JP, Duquette P, Alleva DG, Conlon PJ, Bar-Or A. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin Immunol. 2002; 104 2: 105–114.
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisakk P, Ransohoff RM, Hofbauer M, Farina C, Derfuss T, Hartle C, Newcombe J, Hohlfeld R, Meinl E. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain. 2006; 1 Pt 1: 200–211.
   Google Scholar
• Cepok S, von Geldern G, Grummel V, Hochgesand S, Celik H, Hartung H, Hemmer B. Accumulation of class switched IgD-IgM- memory B cells in the cerebrospinal fluid during neuroinflammation. J Neuroimmunol. 2006; 180 1–2: 33–39.
   Google Scholar
• Teleshova N, Bao W, Kivisakk P, Ozenci V, Mustafa M, Link H. Elevated CD40 ligand expressing blood T-cell levels in multiple sclerosis are reversed by interferon-beta treatment. Scand J Immunol. 2000; 51 3: 312–320.
   Google Scholar
• Pelfrey CM, Moldovan IR, Cotleur AC, Zamor N, Rudick RA. Effects of sex hormones on costimulatory molecule expression in multiple sclerosis. J Neuroimmunol. 2005; 167 1–2: 190–203.
   Google Scholar
• Kosmaczewska A, Bilinska M, Ciszak L, Noga L, Pawlak E, Szteblich A, Podemski R, Frydecka I. Different patterns of activation markers expression and CD4+T-cell responses to ex vivo stimulation in patients with clinically quiescent multiple sclerosis (MS). J Neuroimmunol. 2007; 189 1–2: 137–146.
   Google Scholar
• Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature. 1985; 314 6011: 537–539.
   PubMed Web of Science ®Google Scholar
• Malynn BA, Romeo DT, Wortis HH, Antigen-specific B. cells efficiently present low doses of antigen for induction of T cell proliferation. J Immunol. 1985; 135 2: 980–988.
   Google Scholar
• Sanders VM, Uhr JW, Vitetta ES. Antigen-specific memory and virgin B cells differ in their requirements for conjugation to T cells. Cell Immunol. 1987; 104 2: 419–425.
   Google Scholar
• Bottomly K, Janeway CAJr. Antigen presentation by B cells. Nature. 1989; 337 6202: 24.
   Google Scholar
• Yan J, Harvey BP, Gee RJ, Shlomchik MJ, Mamula MJ. B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation. J Immunol. 2006; 177 7: 4481–4487.
   PubMed Web of Science ®Google Scholar
• O'Neill SK, Shlomchik MJ, Glant TT, Cao Y, Doodes PD, Finnegan A. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol. 2005; 174 6: 3781–3788.
   PubMed Web of Science ®Google Scholar
• Issekutz T, Chu E, Geha RS. Antigen presentation by human B cells: T cell proliferation induced by Epstein Barr virus B lymphoblastoid cells. J Immunol. 1982; 129 4: 1446–1450.
   Google Scholar
• Lombardi G, del Gallo F, Vismara D, Piccolella E, de Martino C, Garzelli C, Puglisi C, Colizzi V. Epstein-Barr virus-transformed B cells process and present Mycobacterium tuberculosis particulate antigens to T-cell clones. Cell Immunol. 1987; 107 2: 281–292.
   Google Scholar
• Vidard L, Kovacsovics-Bankowski M, Kraeft SK, Chen LB, Benacerraf B, Rock KL. Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol. 1996; 156 8: 2809–2818.
   Google Scholar
• Constant S, Schweitzer N, West J, Ranney P, Bottomly K. B lymphocytes can be competent antigen-presenting cells for priming CD4+T cells to protein antigens in vivo. J Immunol. 1995; 155 8: 3734–3741.
   Google Scholar
• Batista FD, Neuberger MS. B cells extract and present immobilized antigen: implications for affinity discrimination. EMBO J. 2000; 19 4: 513–520.
   Google Scholar
• Aluvihare VR, Khamlichi AA, Williams GT, Adorini L, Neuberger MS. Acceleration of intracellular targeting of antigen by the B-cell antigen receptor: importance depends on the nature of the antigen-antibody interaction. EMBO J. 1997; 16 12: 3553–3562.
   Google Scholar
• von Bergwelt-Baildon M, Schultze JL, Maecker B, Menezes I, Nadler LM. Correspondence re R. Lapointe et al., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 2003; 63:2836–2843 Cancer Res 2004;64(11):4055–6; author reply 6–7.
   Google Scholar
• Kleijmeer MJ, Morkowski S, Griffith JM, Rudensky AY, Geuze HJ. Major histocompatibility complex class II compartments in human and mouse B lymphoblasts represent conventional endocytic compartments. J Cell Biol. 1997; 139 3: 639–649.
   Google Scholar
• Chu ET, Lareau M, Rosenwasser LJ, Dinarello CA, Geha RS. Antigen presentation by EBV-B cells to resting and activated T cells: role of interleukin 1. J Immunol. 1985; 134 3: 1676–1681.
   Google Scholar
• Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P, CD40-stimulated B. lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 2003; 63 11: 2836–2843.
   PubMed Web of Science ®Google Scholar
• Burdin N, Rousset F, Banchereau J. B-cell-derived IL-10: production and function. Methods. 1997; 11 1: 98–111.
   Google Scholar
• Arbour N, Lapointe R, Saikali P, McCrea E, Regen T, Antel JP. A new clinically relevant approach to expand myelin specific T cells. J Immunol Methods. 2006; 310 1–2: 53–61.
   Google Scholar
• Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, Gribben JG, Nadler LM. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest. 1997; 100 11: 2757–2765.
   Google Scholar
• Baccam M, Woo SY, Vinson C, Bishop GA. CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-kappa B, AP-1, and C/EBP. J Immunol. 2003; 170 6: 3099–3108.
   Google Scholar
• Rousset F, Garcia E, Banchereau J. Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen. J Exp Med. 1991; 173 3: 705–710.
   Google Scholar
• Splawski JB, Fu SM, Lipsky PE. Immunoregulatory role of CD40 in human B cell differentiation. J Immunol. 1993; 150 4: 1276–1285.
   Google Scholar
• Gray D, Dullforce P, Jainandunsing S. Memory B cell development but not germinal center formation is impaired by in vivo blockade of CD40-CD40 ligand interaction. J Exp Med. 1994; 180 1: 141–155.
   Google Scholar
• von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A, Klein-Gonzalez N, Fiore F, Debey S, Draube A, Maecker B, Menezes I, Nadler LM, Schultze JL. CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood. 2006; 107 7: 2786–2789.
   Google Scholar
• Ahmadi T, Flies A, Efebera Y, Sherr DH. CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I- and class II-binding peptides. Immunology. 2008; 124 1: 129–140.
   Google Scholar
• Bar-Or A, Oliveira EM, Anderson DE, Krieger JI, Duddy M, O'Connor KC, Hafler DA. Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state. J Immunol. 2001; 167 10: 5669–5677.
   Web of Science ®Google Scholar
• Harp CT, Lovett-Racke AE, Racke MK, Frohman EM, Monson NL. Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis. Clin Immunol. 2008; 128 3: 382–391.
   PubMed Web of Science ®Google Scholar
• Harp CT, Ireland S, Davis LS, Remington G, Cassidy B, Cravens PD, Stuve O, Lovett-Racke AE, Eagar TN, Greenberg BM, Racke MK, Cowell LG, Karandikar NJ, Frohman EM, Monson NL. cells from a subset of treatment-naive relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-gamma production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol. 2010; 40 10: 2942–2956.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, Calabresi PA, Waubant E, Hauser SL, Zhang J, Smith CH. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?. Ann Neurol. 2010; 67 4: 452–461.
   PubMed Web of Science ®Google Scholar
• Pistoia V. Production of cytokines by human B cells in health and disease. Immunol Today. 1997; 18 7: 343–350.
   Google Scholar
• Appel H, Neure L, Kuhne M, Braun J, Rudwaleit M, Sieper J. An elevated level of IL-10- and TGFbeta-secreting T cells, B cells and macrophages in the synovial membrane of patients with reactive arthritis compared to rheumatoid arthritis. Clin Rheumatol. 2004; 23 5: 435–440.
   Google Scholar
• Agrawal S, Gupta S. TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. J Clin Immunol. 2011; 31 1: 89–98.
   PubMedGoogle Scholar
• Wagner M, Poeck H, Jahrsdoerfer B, Rothenfusser S, Prell D, Bohle B, Tuma E, Giese T, Ellwart JW, Endres S, Hartmann G. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol. 2004; 172 2: 954–963.
   PubMed Web of Science ®Google Scholar
• Barbosa RR, Silva SP, Silva SL, Melo AC, Pedro E, Barbosa MP, Pereira-Santos MC, Victorino RM, Sousa AE. Primary B-cell deficiencies reveal a link between human IL-17-producing CD4 T-cell homeostasis and B-cell differentiation. PLoS One. 2011; 6 8: e22848.
   PubMed Web of Science ®Google Scholar
• van de Veerdonk FL, Lauwerys B, Marijnissen RJ, Timmermans K, Di Padova F, Koenders MI, Gutierrez-Roelens I, Durez P, Netea MG, van der Meer JW, van den Berg WB, Joosten LA. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 2011; 63 6: 1507–1516.
   PubMedGoogle Scholar
• van de Veerdonk FL, Marijnissen RJ, Kullberg BJ, Koenen HJ, Cheng SC, Joosten I, van den Berg WB, Williams DL, van der Meer JW, Joosten LA, Netea MG. The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe. 2009; 5 4: 329–340.
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang Z, Graner MW, Yang L, Liao M, Yang Q, Gou J, Zhu Y, Wu C, Liu H, Zhou B, Chen X. B cell infiltration is associated with the increased IL-17 and IL-22 expression in the lungs of patients with tuberculosis. Cell Immunol. 2011; 270 2: 217–223.
   Google Scholar
• Yamamoto A, Sato K, Miyoshi F, Shindo Y, Yoshida Y, Yokota K, Nakajima K, Akiba H, Asanuma Y, Akiyama Y, Mimura T. Analysis of cytokine production patterns of peripheral blood mononuclear cells from a rheumatoid arthritis patient successfully treated with rituximab. Mod Rheumatol. 2010; 20 2: 183–187.
   PubMed Web of Science ®Google Scholar
• van de Veerdonk FLLB, Marijnissen RJ, Timmermans K, Di Padova F, Koenders MI, Gutierrez-Roelens I, Durez P, Netea MG, van der Meer JW, van den Berg WB, Joosten LA. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 2011; 63 6: 1507–1516.
   PubMedGoogle Scholar
• Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441 7090: 235–238.
   PubMed Web of Science ®Google Scholar
• Benwell RK, Lee DR. Essential and synergistic roles of IL1 and IL6 in human Th17 differentiation directed by TLR ligand-activated dendritic cells. Clin Immunol. 2010; 134 2: 178–187.
   Google Scholar
• Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006; 441 7090: 231–234.
   PubMed Web of Science ®Google Scholar
• Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007; 8 9: 942–949.
   PubMed Web of Science ®Google Scholar
• Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupe P, Barillot E, Soumelis V. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008; 9 6: 650–657.
   PubMed Web of Science ®Google Scholar
• Cognasse F, Hamzeh-Cognasse H, Lafarge S, Chavarin P, Pozzetto B, Richard Y, Garraud O. Identification of two subpopulations of purified human blood B cells, CD27- CD23+ and CD27high CD80+, that strongly express cell surface Toll-like receptor 9 and secrete high levels of interleukin-6. Immunology. 2008; 125 3: 430–437.
   PubMed Web of Science ®Google Scholar
• Smeland EB, Blomhoff HK, Funderud S, Shalaby MR, Espevik T. Interleukin 4 induces selective production of interleukin 6 from normal human B lymphocytes. J Exp Med. 1989; 170 4: 1463–1468.
   Google Scholar
• Ramgolam VS, Sha Y, Marcus KL, Choudhary N, Troiani L, Chopra M, Markovic-Plese S. B cells as a therapeutic target for IFN-beta in relapsing-remitting multiple sclerosis. J Immunol. 2011; 186 7: 4518–4526.
   PubMed Web of Science ®Google Scholar
• Dienz O, Rincon M. The effects of IL-6 on CD4 T cell responses. Clin Immunol. 2009 Jan; 130 1: 27–33.
   PubMed Web of Science ®Google Scholar
• Banks WA, Kastin AJ, Gutierrez EG. Penetration of interleukin-6 across the murine blood-brain barrier. Neurosci Lett. 1994; 179 1–2: 53–56.
   PubMed Web of Science ®Google Scholar
• Kleine TO, Zwerenz P, Graser C, Zofel P. Approach to discriminate subgroups in multiple sclerosis with cerebrospinal fluid (CSF) basic inflammation indices and TNF-alpha, IL-1beta, IL-6, IL-8. Brain Res Bull. 2003; 61 3: 327–346.
   Google Scholar
• Laurenzi MA, Siden A, Persson MA, Norkrans G, Hagberg L, Chiodi F. Cerebrospinal fluid interleukin-6 activity in HIV infection and inflammatory and noninflammatory diseases of the nervous system. Clin Immunol Immunopathol. 1990; 57 2: 233–241.
   PubMedGoogle Scholar
• Maimone D, Gregory S, Arnason BGW, Reder AT. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol. 1991; 32:67–74.
   PubMed Web of Science ®Google Scholar
• Milman N, Karsh J, Booth RA. Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis. Clin Biochem. 2010; 43 16–17: 1309–1314.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kishimoto T. Immunotherapeutic implication of IL-6 blockade. Immunotherapy. 2012; 4 1: 87–105.
   Google Scholar
• Palmer CD, Mutch BE, Workman S, McDaid JP, Horwood NJ, Foxwell BM. Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NFkapp}B activity. Blood. 2008; 111 4: 1781–1788.
   Google Scholar
• Snir A, Kessel A, Haj T, Rosner I, Slobodin G, Toubi E. Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy. Clin Exp Rheumatol. 2011; 29 4: 697–700.
   PubMed Web of Science ®Google Scholar
• Quintana A, Muller M, Frausto RF, Ramos R, Getts DR, Sanz E, Hofer MJ, Krauthausen M, King NJ, Hidalgo J, Campbell IL. Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J Immunol. 2009; 183 3: 2079–2088.
   Google Scholar
• Gijbels K, Van Damme J, Proost P, Put W, Carton H, Billiau A. Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol. 1990; 20 1: 233–235.
   PubMed Web of Science ®Google Scholar
• Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol. 1998; 28 7: 2178–2187.
   Google Scholar
• Mendel I, Katz A, Kozak N, Ben-Nun A, Revel M. Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. Eur J Immunol. 1998; 28 5: 1727–1737.
   PubMed Web of Science ®Google Scholar
• Samoilova EB, Horton JL, Hilliard B, Liu TS, Chen Y. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol. 1998; 161 12: 6480–6486.
   PubMed Web of Science ®Google Scholar
• Serada S, Fujimoto M, Mihara M, Koike N, Ohsugi Y, Nomura S, Yoshida H, Nishikawa T, Terabe F, Ohkawara T, Takahashi T, Ripley B, Kimura A, Kishimoto T, Naka T. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2008; 105 26: 9041–9046.
   PubMed Web of Science ®Google Scholar
• Gijbels K, Brocke S, Abrams JS, Steinman L. Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation. Mol Med. 1995; 1 7: 795–805.
   PubMed Web of Science ®Google Scholar
• Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008; 7 9: 796–804.
   PubMed Web of Science ®Google Scholar
• van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996; 47 6: 1531–1534.
   PubMed Web of Science ®Google Scholar
• Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001; 44 12: 2862–2869.
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001; 19:683–765.
   PubMed Web of Science ®Google Scholar
• Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol. 1993; 11:165–190.
   PubMed Web of Science ®Google Scholar
• Beebe AM, Cua DJ, de Waal Malefyt R. The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev. 2002; 13 4–5: 403–412.
   PubMed Web of Science ®Google Scholar
• Hanten JA, Vasilakos JP, Riter CL, Neys L, Lipson KE, Alkan SS, Birmachu W. Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol. 2008; 9:39.
   PubMed Web of Science ®Google Scholar
• Itoh K, Hirohata S. The role of IL-10 in human B cell activation, proliferation, and differentiation. J Immunol. 1995; 154 9: 4341–4350.
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991; 174 5: 1209–1220.
   PubMed Web of Science ®Google Scholar
• Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, Kamm MA, Stagg AJ. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology. 2005; 129 1: 50–65.
   Google Scholar
• Ng SC, Plamondon S, Kamm MA, Hart AL, Al-Hassi HO, Guenther T, Stagg AJ, Knight SC. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis. 2010; 16 8: 1286–1298.
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Yssel H, de Vries JE. Direct effects of IL-10 on subsets of human CD4+T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol. 1993; 150 11: 4754–4765.
   Google Scholar
• Koppelman B, Neefjes JJ, de Vries JE, de Waal Malefyt R. Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity. 1997; 7 6: 861–871.
   PubMed Web of Science ®Google Scholar
• Marra LE, Zhang ZX, Joe B, Campbell J, Levy GA, Penninger J, Zhang L. IL-10 induces regulatory T cell apoptosis by up-regulation of the membrane form of TNF-alpha. J Immunol. 2004; 172 2: 1028–1035.
   Google Scholar
• Rodriguez-Sainz Mdel C, Sanchez-Ramon S, de Andres C, Rodriguez-Mahou M, Munoz-Fernandez MA. Th1/Th2 cytokine balance and nitric oxide in cerebrospinal fluid and serum from patients with multiple sclerosis. Eur Cytokine Netw. 2002; 13 1: 110–114.
   PubMed Web of Science ®Google Scholar
• Begum-Haque S, Christy M, Ochoa-Reparaz J, Nowak EC, Mielcarz D, Haque A, Kasper LH. Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate. J Neuroimmunol. 2011; 232 1–2: 136–144.
   PubMed Web of Science ®Google Scholar
• Begum-Haque S, Sharma A, Christy M, Lentini T, Ochoa-Reparaz J, Fayed IF, Mielcarz D, Haque A, Kasper LH. Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010; 219 1–2: 47–53.
   Google Scholar
• Kala M, Rhodes SN, Piao WH, Shi FD, Campagnolo DI, Vollmer TL. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol. 2010; 221 1: 136–145.
   PubMed Web of Science ®Google Scholar
• Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008; 118 10: 3420–3430.
   PubMed Web of Science ®Google Scholar
• Carter NA, Vasconcellos R, Rosser EC, Tulone C, Munoz-Suano A, Kamanaka M, Ehrenstein MR, Flavell RA, Mauri C. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol. 2011; 186 10: 5569–5579.
   PubMed Web of Science ®Google Scholar
• Hirotani M, Niino M, Fukazawa T, Kikuchi S, Yabe I, Hamada S, Tajima Y, Sasaki H. Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis. J Neuroimmunol. 2010; 221 1–2: 95–100.
   PubMed Web of Science ®Google Scholar
• Correale J, Farez M, Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol. 2008; 64 2: 187–199.
   PubMed Web of Science ®Google Scholar
• Knippenberg S, Peelen E, Smolders J, Thewissen M, Menheere P, Cohen Tervaert JW, Hupperts R, Damoiseaux J. Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naive/memory Breg ratio during a relapse but not in remission. J Neuroimmunol. 2011; 239 1–2: 80–86.
   PubMed Web of Science ®Google Scholar
• Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD, Hall RP, St Clair EW, Tedder TF. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011; 117 2: 530–541.
   PubMed Web of Science ®Google Scholar
• Bancos S, Phipps RP. Memory B cells from older people express normal levels of cyclooxygenase-2 and produce higher levels of IL-6 and IL-10 upon in vitro activation. Cell Immunol. 2010; 266 1: 90–97.
   Google Scholar
• Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa A. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med. 1999; 27 7: 1262–1264.
   PubMed Web of Science ®Google Scholar
• Ng PC, Li K, Wong RP, Chui K, Wong E, Li G, Fok TF. Proinflammatory and anti-inflammatory cytokine responses in preterm infants with systemic infections. Arch Dis Child Fetal Neonatal Ed. 2003; 88 3: F209–F213.
   PubMed Web of Science ®Google Scholar
• Yamana J, Yamamura M, Okamoto A, Aita T, Iwahashi M, Sunahori K, Makino H. Resistance to IL-10 inhibition of interferon gamma production and expression of suppressor of cytokine signaling 1 in CD4+T cells from patients with rheumatoid arthritis. Arthritis Res Ther. 2004; 6 6: R567–R577.
   Google Scholar
• Korporal M, Haas J, Balint B, Fritzsching B, Schwarz A, Moeller S, Fritz B, Suri-Payer E, Wildemann B. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells. Arch Neurol. 2008; 65 11: 1434–1439.
   Google Scholar
• Liu Z, Pelfrey CM, Cotleur A, Lee JC, Rudick RA. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol. 2001; 112 1–2: 153–162.
   Google Scholar
• Jiang H, Milo R, Swoveland P, Johnson KP, Panitch H, Dhib-Jalbut S. Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells. J Neuroimmunol. 1995; 61 1: 17–25.
   Google Scholar
• Christophi GP, Panos M, Hudson CA, Tsikkou C, Mihai C, Mejico LJ, Jubelt B, Massa PT. Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1. Clin Immunol. 2009; 133 1: 27–44.
   Google Scholar
• Cruz M, Olsson T, Ernerudh J, Hojeberg B, Link H. Immunoblot detection of oligoclonal anti-myelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis. Neurology. 1987; 37 9: 1515–1519.
   PubMed Web of Science ®Google Scholar
• Warren KG, Catz I. Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. J Neurol Sci. 1994; 121 1: 66–73.
   Google Scholar
• Cash E, Weerth S, Voltz R, Kornhuber M. Cells of cerebrospinal fluid of multiple sclerosis patients secrete antibodies to myelin basic protein in vitro. Scand J Immunol. 1992; 35 6: 695–701.
   Google Scholar
• Gerritse K, Deen C, Fasbender M, Ravid R, Boersma W, Claassen E. The involvement of specific anti myelin basic protein antibody-forming cells in multiple sclerosis immunopathology. J Neuroimmunol. 1994; 49 1–2: 153–159.
   Google Scholar
• Fridkis-Hareli M, Teitelbaum D, Gurevich E, Pecht I, Brautbar C, Kwon OJ, Brenner T, Arnon R, Sela M. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells–specificity and promiscuity. Proc Natl Acad Sci USA. 1994; 91 11: 4872–4876.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Ifergan I, Antel JP, Seguin R, Duddy M, Lapierre Y, Jalili F, Bar-Or A. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol. 2004; 172 11: 7144–7153.
   PubMed Web of Science ®Google Scholar
• Weber MS, Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain. 2004; 6 Pt 6: 1370–1378.
   Google Scholar